Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Finlabo SIM Spa
$10.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA's Genzyme's Lemtrada approved in Australia for treatment of multiple sclerosis


Thursday, 19 Dec 2013 08:00am EST 

Sanofi SA:Says its Genzyme's Lemtrada (alemtuzumab) has been approved by the Australian Therapeutic Goods Administration (TGA).Says the drug has been approved for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses. 

Company Quote

88.76
0.3 +0.34%
11:38am EDT